Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioid Approval Standards Not Up For Debate, FDA Tells Advisory Cmte.

Executive Summary

As Egalet's Arymo ER heads to panel, agency tries to head off discussion about whether it should be approving new opioid products and whether longer clinical efficacy trials should be demanded.

Advertisement

Related Content

NIH Advisors Back Insuring Complementary, Alternative Solutions To Drugs For Health Care
Egalet's Arymo ER Opioid Has Questionable Oral Abuse-Deterrent Effect
Egalet's Arymo ER Opioid Has Questionable Oral Abuse-Deterrent Effect
Keeping Track: More Bumps On The Abuse-Deterrent Opioid Road
Opioid Clinical Efficacy Standards Need Rethinking, FDA Panel Says
Opioids Need Post-Marketing Data To Inform Abuse-Deterrent Claims, FDA Panel Says
Teva's Vantrela Gets FDA Panel Nod For Three Abuse-Deterrent Claims
KemPharm's Opioid Apadaz Will Likely Miss Out On Abuse Deterrence Claim
Opioid REMS Prescriber Education Should Be Mandatory, FDA Panel Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118889

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel